Triamcinolone acetonide inhibits p38MAPK activation and neuronal apoptosis in early diabetic retinopathy

Current Molecular Medicine

Volumn 13, Issue 6, 2013, Pages 946-958

  Zhang, X ^a,b,c   Lai, D ^d   Bao, S ^d   Hambly, B D ^d   Gillies, M C ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Beijing Ophthalmology and Visual Science Key Laboratory   (China)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Apoptosis; Diabetic macular edema; Diabetic retinopathy; Neuro protection; Protein phosphorylation; Triamcinolone acetonide

Indexed keywords

CASPASE 3; COMPLEMENTARY DNA; GLUCOCORTICOID RECEPTOR; ISOENZYME; KENACORT A 40; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P85; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL COUNT; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DOWN REGULATION; ENZYME ACTIVATION; GENE EXPRESSION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; INTRACELLULAR SIGNALING; MALE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RETINA NERVE CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; WESTERN BLOTTING;

RATTUS;

EID: 84881339273     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524011313060007     Document Type: Article

References (44)

1. Antonetti DA, Barber AJ, Bronson S, et al. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 2006; 55(9): 2401-2411.
2. Bresnick GH. Diabetic retinopathy viewed as a neurosensory disorder. Arch Ophthalmol 1986; 104(7): 989-990.
3. Barber AJ, Lieth E, Khin SA, et al. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 1998; 102(4): 783-791.
4. Gastinger MJ, Singh RS, Barber AJ. Loss of cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. Invest Ophthalmol Vis Sci 2006; 47(7): 3143-3150.
5. Zhang J, Wu Y, Jin Y, et al. Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol Vis Sci 2008; 49(2): 732-742.
6. Luo XL, Sahel, JA et al. Hypoglycemia induces general neuronal death, whereas hypoxia and glutamate transport blockade lead to selective retinal ganglion cell death in vitro. Invest Ophthalmol Vis Sci 2001; 42(11): 2695-2705.
7. Corrochano S, Barhoum R, Boya P, et al. Attenuation of vision loss and delay in apoptosis of photoreceptors induced by proinsulin in a mouse model of retinitis pigmentosa. Invest Ophthalmol Vis Sci 2008; 49(9): 4188-4194.
8. Jiang S, Moriarty-Craige SE, Orr M, et al. Oxidant-induced apoptosis in human retinal pigment epithelial cells: dependence on extracellular redox state. Invest Ophthalmol Vis Sci 2005; 46(3): 1054-1061.
9. El-Remessy AB, Al-Shabrawey M, Khalifa Y, et al. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol 2006; 168(1): 235-244.
10. Wang XJ, Kong KM, Qi WL, Ye WL, Song PS. Interleukin-1 beta induction of neuron apoptosis depends on p38 mitogen-activated protein kinase activity after spinal cord injury. Acta Pharmacol Sin 2005; 26(8): 934-942.
11. Piao C, Kim J, Han P, Lee J. Administration of the p38 MAPK inhibitor SB203580 affords brain protection with a wide therapeutic window against focal ischemic insult. Journal of Neuroscience Research 2003; 73(4): 537-544.
12. Han J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994; 265(5173): 808-811.
13. Jiang Y, Chen C, Li Z, et al. Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J Biol Chem 1996; 271(30): 17920-17926.
14. Jiang Y, Gram H, Zhao M, et al. Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38delta. J Biol Chem 1997; 272(48): 30122-30128.
15. Li Z, Jiang Y, Ulevitch RJ, Han J. The Primary Structure of p38[gamma]: A New Member of p38 Group of MAP Kinases. Biochem Biophys Res Commun 1996; 228(2): 334-340.
16. Guo G, Bhat NR. p38alpha MAP kinase mediates hypoxia-induced motor neuron cell death: a potential target of minocycline's neuroprotective action. Neurochem Res 2007; 32(12): 2160-2166.
17. Tamagno E, Robino G, Obbili A, et al. H2O2 and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK. Exp Neurol 2003; 180(2): 144-155.
18. Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006; 113(9): 1533-1538.
19. Glybina IV, Kennedy A, Ashton P, Abrams GW, Iezzi R. Intravitreous delivery of the corticosteroid fluocinolone acetonide attenuates retinal degeneration in S334ter-4 rats. Invest Ophthalmol Vis Sci 2010; 51(8): 4243-4252.
20. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007; 125(3): 309-317.
21. Bhisitkul RB, Winn BJ, Lee OT, et al. Neuroprotective effect of intravitreal triamcinolone acetonide against photoreceptor apoptosis in a rabbit model of subretinal hemorrhage. Invest Ophthalmol Vis Sci 2008; 49(9): 4071-4077.
22. Wenzel A, Grimm C, Seeliger MW, et al. Prevention of photoreceptor apoptosis by activation of the glucocorticoid receptor. Invest Ophthalmol Vis Sci 2001; 42(7): 1653-1659.
23. Zhang X, Bao S, Lai D, Rapkins RW, Gillies MC. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes 2008; 57(4): 1026-1033.
24. Curtin F, Schulz P. Multiple correlations and bonferroni's correction. Biol Phychiatry 1998; 44(8): 775-777.
25. Lopes de Faria JM, Russ H, Costa VP. Retinal nerve fibre layer loss in patients with type 1 diabetes mellitus without retinopathy. Br J Ophthalmol 2002; 86(7): 725-728.
26. Chihara E, Matsuoka T, Ogura Y, Matsumura M. Retinal nerve fiber layer defect as an early manifestation of diabetic retinopathy. Ophthalmology 1993; 100(8): 1147-1151.
27. Ejaz S, Chekarova I, Ejaz A, Sohail A, Lim CW. Importance of pericytes and mechanisms of pericyte loss during diabetic retinopathy. Diabetes Obes Metab 2008; 10(1): 53-63.
28. Saccani S, Pantano S, Natoli G. p38-dependent marking of inflammatory genes for increased NF-[kappa]B recruitment. Nat Immunol 2002; 3(1): 69-75.
29. Igarashi M, Wakasaki H, Takahara N, et al. Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. J Clin Invest 1999; 103(2): 185-195.
30. New L, Han J. The p38 MAP kinase pathway and its biological function. Trends Cardiovasc Med 1998; 8(5): 220-228.
31. Chi H, Flavell RA. Acetylation of MKP-1 and the control of inflammation. Sci Signal 2008; 1(41): pe44.
32. Choi BH, Hur EM, Lee JH, Jun DJ, Kim KT. Protein kinase Cdelta-mediated proteasomal degradation of MAP kinase phosphatase-1 contributes to glutamate-induced neuronal cell death. J Cell Sci 2006; 119(Pt 7): 1329-1340.
33. McLaughlin B, Pal S, Tran MP, et al. p38 Activation is required upstream of potassium current enhancement and caspase cleavage in thiol oxidant-induced neuronal apoptosis. J Neurosci 2001; 21(10): 3303-3311.
34. Sarker KP, Nakata M, Kitajima I, Nakajima T, Maruyama I. Inhibition of caspase-3 activation by SB 203580, p38 mitogen-activated protein kinase inhibitor in nitric oxide-induced apoptosis of PC-12 cells. J Mol Neurosci 2000; 15(3): 243-250.
35. Andrade F, Roy S, Nicholson D, et al. Granzyme B directly and efficiently cleaves several downstream caspase substrates: implications for CTL-induced apoptosis. Immunity 1998; 8(4): 451-460.
36. Wang Z, Frederick J, Garabedian MJ. Deciphering the phosphorylation code of the glucocorticoid receptor in vivo. J Biol Chem 2002; 277(29): 26573-26580.
37. Wu W, Pew T, Zou M, Pang D, Conzen SD. Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J Biol Chem 2005; 280(6): 4117-4124.
38. Fung A, Lalwani G, Rosenfeld P, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143(4): 566-583.
39. Apte RS, Modi M, Masonson H, et al. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology 2007; 114(9): 1702-1712.
40. Zachary I. Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. Neurosignals 2005; 14(5): 207-221.
41. Silverman WF, Krum JM, Mani N, Rosenstein JM. Vascular, glial and neuronal effects of vascular endothelial growth factor in mesencephalic explant cultures. Neuroscience 1999; 90(4): 1529-1541.
42. Tsurumi Y, Takeshita S, Chen D, et al. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996; 94(12): 3281-3290.
43. Gillies MC. What we don't know about avastin might hurt us. Arch Ophthalmol 2006; 124(10): 1478-1479.
44. Glybina IV, Kennedy A, Ashton P, Abrams GW, Iezzi R. Intravitreous delivery of the corticosteroid fluocinolone acetonide attenuates retinal degeneration in S334ter-4 rats. Invest Ophthalmol Vis Sci 2010; 51(8): 4243-4252.